Personalis (PSNL)

• Market cap: $406M
• 1 day: 9.32%
• 5 days: 50.52%
• 1 month: 66.18%
• 3 months: 0.17%
• 6 months: 367.48%
• Year to date: 181.86%
• 1 year: 293.84%
• 5 years: -40.72%
• 10 years: -79.82%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Employees: 225

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

510% more capital invested

Capital invested by funds: $25.8M [Q2] → $158M (+$132M) [Q3]

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

20% more funds holding

Funds holding: 69 [Q2] → 83 (+14) [Q3]

12.6% more ownership

Funds ownership: 42.52% [Q2] → 55.11% (+12.6%) [Q3]

39% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 28

60% less call options, than puts

Call options by funds: $183K | Put options by funds: $459K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7.25 26% upside
• Avg. target: $9.13 59% upside
• High target: $11 91% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson 50% 1-year accuracy 58 / 117 met price target	26% upside $7.25	Buy Reiterated	20 Dec 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	91% upside $11	Buy Maintained	20 Dec 2024